IROS, Prilenia a International Huntington's Disease Association spolupracují na vůbec první studii Huntingtonovy choroby (HD) v regionu MENA.
Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial Číst více...